Catherine Stedman
New Zealand pharmacologist and gastroenterologist
From Wikipedia, the free encyclopedia
Catherine Ann Malcolm Stedman is a New Zealand pharmacologist and gastroenterologist, and is a clinical professor at the University of Otago, specialising in hepatitis C drug development. She is the first woman gastroenterologist to become a professor of medicine in New Zealand.
- Role of nuclear receptors in bile acid disposition and detoxification (2006)
- Pharmacology
- gastroenterology
Catherine Stedman | |
|---|---|
| Children | William Stedman |
| Academic background | |
| Alma mater | University of Sydney |
| Thesis |
|
| Academic work | |
| Discipline |
|
| Institutions | University of Otago |
| Website | University of Otago profile |
Academic career
Stedman completed her undergraduate medical degree at the University of Otago, and then undertook a PhD titled Role of nuclear receptors in bile acid disposition and detoxification at the University of Sydney in 2006.[1] Her clinical training in pharmacology and gastroenterology took place at Christchurch Hospital and Westmead Hospital in Sydney.[2] Stedman then worked in the Salk Institute, and on drug safety for a pharmaceutical company.[2] Stedman returned to Christchurch Hospital as a consultant gastroenterologist and joined the faculty of the University of Otago, rising to clinical associate professor in 2015 and full professor in 2023.[3][4] She is the first woman gastroenterologist to become a professor of medicine in New Zealand.[2]
Stedman's research focuses on drug development for hepatitis C treatment, although she is also interested in autoimmune liver diseases, and how they affect the lives and life expectancy of people who have them. Stedman has been a principal investigator in a large number of clinical trials aimed at testing antiviral therapies, and led the first successful clinical trial in the world to show that oral antiviral treatment could cure hepatitis C.[4] Stedman has also led trials for antiviral therapies aimed at patients with liver failure resulting from hepatitis C.[4] As a result of these trials, and other potential therapies, the World Health Organization has proposed elimination of hepatitis C.[4][5][6][7]
As of 2024, Stedman is the president of the New Zealand Society of Gastroenterology.[2]
Honours and awards
In 2019 Stedman was awarded the Gold Research Medal by the University of Otago Christchurch campus.[8]
Selected works
- Graham R. Foster; Nezam Afdhal; Stuart K. Roberts; et al. (17 November 2015). "Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection". The New England Journal of Medicine. 373 (27): 2608–2617. doi:10.1056/NEJMOA1512612. ISSN 0028-4793. PMID 26575258. Wikidata Q40907444.
{{cite journal}}: CS1 maint: numeric names: authors list (link) - Susanna Naggie; Curtis Cooper; Michael Saag; et al. (21 July 2015). "Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1". The New England Journal of Medicine. 373 (8): 705–713. doi:10.1056/NEJMOA1501315. ISSN 0028-4793. PMC 4892372. PMID 26196665. Wikidata Q36967076.
{{cite journal}}: CS1 maint: numeric names: authors list (link) - Edward J. Gane; Stuart K. Roberts; Catherine A. M. Stedman; et al. (14 October 2010). "Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial". The Lancet. 376 (9751): 1467–1475. doi:10.1016/S0140-6736(10)61384-0. ISSN 0140-6736. PMID 20951424. Wikidata Q42857015.
- Devin Razavi-Shearer; Ivane Gamkrelidze; Mindie H Nguyen; et al. (June 2018). "Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study". The lancet. Gastroenterology & hepatology. 3 (6): 383–403. doi:10.1016/S2468-1253(18)30056-6. ISSN 2468-1253. PMID 29599078. Wikidata Q56830540.
- Catherine A M Stedman; Christopher Liddle; Sally A Coulter; Junichiro Sonoda; Jacqueline G A Alvarez; David D Moore; Ronald M Evans; Michael Downes (31 January 2005). "Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury". Proceedings of the National Academy of Sciences of the United States of America. 102 (6): 2063–2068. Bibcode:2005PNAS..102.2063S. doi:10.1073/PNAS.0409794102. ISSN 0027-8424. PMC 548592. PMID 15684063. Wikidata Q33838275.
- Catherine Stedman; Christopher Liddle; Sally Coulter; Junichiro Sonoda; Jacqueline G Alvarez; Ronald M Evans; Michael Downes (14 July 2006). "Benefit of farnesoid X receptor inhibition in obstructive cholestasis". Proceedings of the National Academy of Sciences of the United States of America. 103 (30): 11323–11328. Bibcode:2006PNAS..10311323S. doi:10.1073/PNAS.0604772103. ISSN 0027-8424. PMC 1544085. PMID 16844773. Wikidata Q34983994.
- Ira M Jacobson; Eric Lawitz; Edward J Gane; et al. (5 April 2017). "Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials". Gastroenterology. 153 (1): 113–122. doi:10.1053/J.GASTRO.2017.03.047. ISSN 0016-5085. PMID 28390869. Wikidata Q40251971.
- Catherine Stedman (1 January 2002). "Herbal hepatotoxicity". Seminars in Liver Disease. 22 (2): 195–206. doi:10.1055/S-2002-30104. ISSN 0272-8087. PMID 12016550. Wikidata Q34643156.